Patents by Inventor Juan Lorenzo

Juan Lorenzo has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20140051721
    Abstract: The present invention refers to a stable crystalline salt of (R)-3-fluorophenyl-3,4,5-trifluorobenzylcarbamic acid 1-azabicyclo [2.2.
    Type: Application
    Filed: February 8, 2013
    Publication date: February 20, 2014
    Applicant: LABORATORIOS SALVAT, S.A.
    Inventors: Juan Lorenzo CATENA RUIZ, José HILDALGO RODRÍGUEZ, María del Carmen SERRA COMAS, Isabel MASIP MASIP
  • Publication number: 20130303522
    Abstract: The compounds of formula (I) are derived from perhydroquinoline and perhydroisoquinoline and are useful as active pharmaceutical ingredients for the prophylaxis or treatment of diseases caused by 11-beta-hydroxysteroid dehydrogenase type 1 (11-beta-HSD1) enzyme-associated disorders, such as glaucoma, elevated ocular pressure, metabolic disorders, obesity, metabolic syndrome, dyslipidemia, hypertension, diabetes, atherosclerosis, Cushing's syndrome, psoriasis, rheumatoid arthritis, cognitive disorders, Alzheimer's disease or neurodegeneration.
    Type: Application
    Filed: July 22, 2013
    Publication date: November 14, 2013
    Applicant: LABORATORIOS SALVAT, S.A.
    Inventors: Juan Lorenzo CATENA RUIZ, Carme SERRA COMAS, Oscar REY PUIGGROS, Albert ANTOLIN HERNANDEZ, Esther MONLLEO MAS
  • Patent number: 8524894
    Abstract: The compounds of formula (I) are derived from perhydroquinoline and perhydroisoquinoline and are useful as active pharmaceutical ingredients for the prophylaxis or treatment of diseases caused by 11-beta-hydroxysteroid dehydrogenase type 1 (11-beta-HSD1) enzyme-associated disorders, such as glaucoma, elevated ocular pressure, metabolic disorders, obesity, metabolic syndrome, dyslipidemia, hypertension, diabetes, atherosclerosis, Cushing's syndrome, psoriasis, rheumatoid arthritis, cognitive disorders, Alzheimer's disease or neurodegeneration.
    Type: Grant
    Filed: June 4, 2010
    Date of Patent: September 3, 2013
    Assignee: Laboratorios Salvat, S.A.
    Inventors: Juan Lorenzo Catena Ruiz, Carme Serra Comas, Oscar Rey Puiggros, Albert Antolin Hernandez, Esther Monlleo Mas
  • Patent number: 8492402
    Abstract: The present invention refers to a stable crystalline salt of (R)-3-fluorophenyl-3,4,5-trifluorobenzylcarbamic acid 1-azabicyclo[2.2.2]oct-3-yl ester and its use as medicament, in particular for the treatment of urinary incontinence or other diseases involving genitourinary disorders.
    Type: Grant
    Filed: November 26, 2008
    Date of Patent: July 23, 2013
    Assignee: Laboratorios Salvat, S.A.
    Inventors: Juan Lorenzo Catena Ruiz, José Hidalgo Rodriguez, María del Carmen Serra Comas, Isabel Masip Masip
  • Publication number: 20120253381
    Abstract: A stretch-resistant occlusive device having an elongated, substantially cylindrical porous elastomeric structure and at least one of an elongated stretch-resistant tube and at least one stretch-resistant filament. The porous structure lies within an elongated outer embolic structure such as a helically wound embolic coil.
    Type: Application
    Filed: March 31, 2011
    Publication date: October 4, 2012
    Applicant: Codman & Shurtleff, Inc.
    Inventors: PETER FORSYTHE, JUAN LORENZO
  • Publication number: 20120253377
    Abstract: An occlusive device suitable for endovascular treatment of an aneurysm in a region of a parent vessel in a patient, including a structure having a fixed porosity and having dimensions suitable for insertion into vasculature of the patient to reach the region of the aneurysm in the parent vessel. The device further includes a frangible material supported by the structure which initially provides a substantial barrier to flow through the frangible material and is capable of at least one of localized rupturing and localized eroding, in the presence of a pressure differential arising at an ostium of a perforator vessel communicating with the parent vessel, within an acute time period to minimize ischemia downstream of the perforator vessel.
    Type: Application
    Filed: March 31, 2011
    Publication date: October 4, 2012
    Applicant: CODMAN & SHURTLEFF, INC.
    Inventors: Robert Slazas, Juan Lorenzo, Peter Forsythe
  • Publication number: 20120071466
    Abstract: The compounds of formula (I) are derived from perhydroquinoline and perhydroisoquinoline and are useful as active pharmaceutical ingredients for the prophylaxis or treatment of diseases caused by 11-beta-hydroxysteroid dehydrogenase type I (11-beta-HSD1) enzyme-associated disorders, such as glaucoma, elevated ocular pressure, metabolic disorders, obesity, metabolic syndrome, dyslipidemia, hypertension, diabetes, atherosclerosis, Cushing's syndrome, psoriasis, rheumatoid arthritis, cognitive disorders, Alzheimer's disease or neurodegeneration.
    Type: Application
    Filed: June 4, 2010
    Publication date: March 22, 2012
    Inventors: Juan Lorenzo Catena Ruiz, Carme Serra Comas, Oscar Rey Puiggros, Albert Antolin Hernandez, Esther Monlleomas
  • Publication number: 20110313443
    Abstract: A stretch-resistant occlusive device, and method of manufacturing such a device, having a helically wound coil defining a coil lumen extending along the entire axial length of the coil from a proximal end portion to a distal end portion. The device further includes a headpiece having a proximal end, a distal end attached to the proximal end portion of the coil, and a headpiece lumen extending between the proximal and distal ends of the headpiece. An anchor filament extends through the headpiece lumen, has at least one proximal end secured to the proximal end of the headpiece, and has a distal portion defining an eye positioned distal to the distal end of the headpiece. A stretch resistant member is positioned within the coil lumen, has a proximal portion extending through the eye, and has at least one distal end secured to the distal end of the coil.
    Type: Application
    Filed: June 16, 2010
    Publication date: December 22, 2011
    Applicant: CODMAN & SHURTLEFF, INC.
    Inventors: Juan Lorenzo, Robert Slazas, Peter Forsythe, Thomas Boden, Michael Brown
  • Publication number: 20110207769
    Abstract: The present invention refers to a stable crystalline salt of (R)-3-fluorophenyl-3,4,5-trifluorobenzylcarbamic acid 1-azabicyclo[2.2.
    Type: Application
    Filed: November 26, 2008
    Publication date: August 25, 2011
    Applicant: LABORATORIOS SALVAT, S.A.
    Inventors: Juan Lorenzo Catena Ruiz, José Hidalgo Rodriguez, Maria del Carmen Serra Comas, Isabel Masip Masip
  • Patent number: 7838534
    Abstract: Quinuclidine derivative of the general formula (I) in the form of single enantiomers or mixtures thereof are useful in the manufacture of a medicament for the prevention and therapy of respiratory diseases such as asthma, chronic obstructive pulmonary disease (COPD), chronic bronchitis, cough and emphysema wherein: R1 is selected from H, F, Cl, Br, I and (C1-C4)-alkyl; R2 is optionally substituted 2- or 3-thienyl, or substituted phenyl; R3 is (CH2)1-4—COR4 or (CH2)1-4—S(O)nR4, wherein R4 is optionally substituted phenyl or optionally substituted 2- or 3-thienyl; n is 0, 1 or 2; X? is a pharmaceutically acceptable anion.
    Type: Grant
    Filed: July 25, 2007
    Date of Patent: November 23, 2010
    Assignee: Chiesi Farmaceutici S.p.A.
    Inventors: Gabriele Amari, Andrea Rizzi, Riccardo Patacchini, Valentina Cenacchi, Gino Villetti, Juan Lorenzo Catena Ruiz, Isabel Masip Masip
  • Publication number: 20100075984
    Abstract: Compounds of formula (I), and their pharmaceutically acceptable salts and solvates, wherein X represents —O—, —NH—, —S—, —NHC(?O)— or —NHC(?S)—; R1 represents —H or a hydrocarbon chain; R2 represents —H, alkoxy, amino, a hydrocarbon chain or a radical of a cycle; R3 represents —H, a hydrocarbon chain or a radical of a cycle; R4 represents —H or a hydrocarbon chain; alternatively R3 and R4 form together a cycle; R5 and R6 represent —H or halogen, and R7 represents —H, a hydrocarbon chain or heteroaryl, are useful against bacterial infections in animals, including humans.
    Type: Application
    Filed: January 18, 2007
    Publication date: March 25, 2010
    Applicant: LABORATORIOS SALVAT, S.A.
    Inventors: José Hidalgo Rodríguez, Juan Lorenzo Catena Ruiz, Isabel Masip Masip, Maria del Carmen Serra Comas, Oscar Rey Puiggrós, Carmen Lagunas Arnal, Carolina Salcedo Roca, Dolors Balsa López
  • Publication number: 20090088438
    Abstract: Compounds of general formula I, and the salts and solvates thereof, wherein R1 represents the radical 2-benzoylphenylamino; R2 represents —(CH2)s—N(COR3)-A-J-T or —(CH2)s—N(R4)-B-J-T; and s, R3, R4, A, B, J and T have the meanings disclosed herein. These compounds are PPAR? modulators and, therefore, are useful for the treatment or prevention of a condition or a disease mediated by these receptors.
    Type: Application
    Filed: June 25, 2008
    Publication date: April 2, 2009
    Applicant: LABORATORIOS SALVAT, S.A.
    Inventors: Carmen SERRA COMAS, Anna FERNANDEZ SERRAT, Dolors BALSA LOPEZ, Isabel MASIP MASIP, Juan Lorenzo CATENA RUIZ, Jose HIDALGO RODRIGUEZ, Carmen LAGUNAS ARNAL, Carolina SALCEDO ROCA, Andres FERNANDEZ GARCIA
  • Patent number: 7452904
    Abstract: Carbamate of general formula (I), wherein R1, R2, and R3 are H, OH, NO2, SH, CN, F, Cl, Br, I, COOH, CONH2, (C1-C4)-alkoxycarbonyl, (C1-C4)-alkylsulfanyl, (C1-C4)-alkylsulfinyl, (C1-C4)-alkylsulfonyl, (C1-C4)-alkoxyl optionally substituted with one or several F, and (C1-C4)-alkyl optionally substituted with one or several F or OH; R4 is cycloalkyl, phenyl, heteroaryl or a bicyclic ring system; R5 is cycloalkyl, (C5-C10)-alkyl, a substituted (C1-C10)-alkyl; and X? is a physiologically acceptable anion. Carbamate (I) is selective M3 receptor antagonists versus M2 receptor and may be used for the treatment of urinary incontinence (particularly, the one caused by overactive bladder), irritable bowel syndrome, and respiratory disorders (particularly, chronic obstructive pulmonary disease, chronic bronchitis, asthma, emphysema, and rhinitis), as well as in ophthalmic interventions.
    Type: Grant
    Filed: December 18, 2002
    Date of Patent: November 18, 2008
    Assignee: Chiesi Farmaceutici S.p.A.
    Inventors: Juan Lorenzo Catena Ruiz, Carles Farrerons Gallemi, Anna Fernandez Serrat, Ignacio José Miquel Bono, Dolors Balsa Lopez, Carmen Lagunas Arnal, Carolina Salcedo Roca, Natividad Toledo Mesa, Andrés Fernandez Garcia
  • Patent number: 7423172
    Abstract: Compounds of general formula I, and the salts and solvates thereof, wherein R1 represents the radical 2-benzoylphenylamino; R2 represents —(CH2)s—N(COR3)-A-J-T or —(CH2)s—N(R4)—B-J-T; and s. R3, R4, A, B, J and T have the meanings disclosed in the description. These compounds are PPAR? modulators and, therefore, are useful for the treatment or prevention of a condition or a disease mediated by these receptors.
    Type: Grant
    Filed: July 29, 2005
    Date of Patent: September 9, 2008
    Assignee: Laboratorios Salvat, S.A.
    Inventors: Carmen Serra Comas, Anna Fernández Serrat, Dolors Balsa López, Isabel Masip Masip, Juan Lorenzo Catena Ruiz, José Hidalgo Rodriguez, Carmen Lagunas Arnal, Carolina Salcedo Roca, Andrés Fernández García
  • Publication number: 20080097495
    Abstract: Thin film metallic devices implantable within a human subject for occlusion of an aneurysm or blood vessel are provided. The devices are movable from a porous, elongated, collapsed configuration for delivery to a deployed configuration within the body. The pores telescope as the device moves to its deployed configuration, which causes the device to longitudinally foreshorten and radially expand, while also decreasing in porosity for preventing blood flow. The occlusion devices may be either self-supporting or supported by a strut structure. Additionally, the occlusion devices may comprise a plurality of layers having unaligned pore systems which further reduce porosity in the deployed configuration.
    Type: Application
    Filed: September 16, 2005
    Publication date: April 24, 2008
    Inventors: Frederick Feller lll, Juan Lorenzo
  • Publication number: 20070276043
    Abstract: Compounds of general formula I, and the salts and solvates thereof, wherein R1 represents the radical 2-benzoylphenylamino; R2 represents —(CH2)s—N(COR3)-A-J-T or —(CH2)S—N(R4)—B-J-T; and s, R3, R4, A, B, J and T have the meanings disclosed in the description. These compounds are PPAR? modulators and, therefore, are useful for the treatment or prevention of a condition or a disease mediated by these receptors.
    Type: Application
    Filed: July 29, 2005
    Publication date: November 29, 2007
    Inventors: Carmen Serra Comas, Anna Fernandez Serrat, Dolors Balsa Lopez, Isabel Masip Masip, Juan Lorenzo Catena Ruiz, Jose Hidalgo Rodriguez, Carmen Lagunas Arnal, Carolina Salcedo Roca, Andres Fernandez Garcia
  • Publication number: 20070255253
    Abstract: A vascular occlusive device which includes a vascular occlusive embolic coil, a bioactive coating disposed onto the embolic coil, and an outer barrier coating which serves to prevent a reaction between the bioactive agent in the bioactive coating and bodily fluids, until the outer barrier is activated by applying an external agent to the outer barrier.
    Type: Application
    Filed: June 22, 2007
    Publication date: November 1, 2007
    Inventors: Donald Jones, Juan Lorenzo, Mark Pomeranz, Darren Sherman
  • Publication number: 20070203519
    Abstract: A vascular occlusion device deployment system for deploying an occlusion device at a preselected site within the vasculature of a patient. The deployment system includes a pusher which has a constrictor located at the distal end portion of the pusher. The constrictor has a channel which receives a portion of the occlusion device. The constrictor has a proximal end portion and a distal end portion wherein the proximal end portion can be moved relative to the distal end portion to reduce the size of the channel. When the channel size is reduced, the constrictor grasps the portion of the occlusion device located within the channel. When it is desired to deploy the coil, the constrictor is moved in the opposite direction to increase the size of the channel and release the coil's grasp of the occlusion device.
    Type: Application
    Filed: February 28, 2006
    Publication date: August 30, 2007
    Inventors: Juan Lorenzo, Vladimir Mitelberg, Donald Jones
  • Publication number: 20060276825
    Abstract: A medical device for placing an embolic device at a predetermined site within a vessel of the body including a delivery catheter and a flexible pusher member having a lumen therethrough and being slidably disposed within the lumen of the catheter. A stretch resistant embolic device is retained within the delivery catheter by a mechanical interlocking mechanism which includes an engagement member which is attached to the distal end of the pusher member and extends through a retaining ring at the proximal end of the embolic device. A detachment member extends through an aperture at the distal end of the engagement member thereby locking the embolic device onto the pusher member. The engagement member engages a retaining ring on the embolic device. When the embolic device is advanced to the predetermined site within the vessel, the detachment member is withdrawn from the aperture to thereby release the embolic device at the treatment site.
    Type: Application
    Filed: June 30, 2005
    Publication date: December 7, 2006
    Inventors: Vladimir Mitelberg, Donald Jones, Juan Lorenzo
  • Publication number: 20060276827
    Abstract: A medical device for placing an embolic device at a predetermined site within a vessel of the body including a delivery catheter and a flexible pusher member having a lumen therethrough and being slidably disposed within the lumen of the catheter. A stretch resistant embolic device is retained within the delivery catheter by a mechanical interlocking mechanism which includes an engagement member which is slidably disposed within the pusher member and extends through a retaining ring at the proximal end of the embolic device. A detachment member extends through an aperture at the distal end of the engagement member thereby locking the embolic device onto the engagement member. The engagement member engages a retaining ring on the embolic device. When the embolic device is advanced to the predetermined site within the vessel, the detachment member is withdrawn from the aperture to thereby release the embolic device at the treatment site.
    Type: Application
    Filed: June 30, 2005
    Publication date: December 7, 2006
    Inventors: Vladimir Mitelberg, Donald Jones, Juan Lorenzo